Literature DB >> 21555214

Fragile X syndrome and the amygdala.

Aparna Suvrathan1, Sumantra Chattarji.   

Abstract

Fragile X syndrome (FXS) is the most commonly inherited form of mental impairment and autism. Current understanding of the molecular and cellular mechanisms underlying FXS symptoms is derived mainly from studies on the hippocampus and cortex. However, FXS is also associated with strong emotional symptoms, which are likely to involve changes in the amygdala. Unfortunately, the synaptic basis of amygdalar dysfunction in FXS remains largely unexplored. Here we describe recent findings from mouse models of FXS that have identified synaptic defects in the basolateral amygdala that are in many respects distinct from those reported earlier in the hippocampus. Long-term potentiation and surface expression of AMPA-receptors are impaired. Further, presynaptic defects are seen at both excitatory and inhibitory synapses. Remarkably, some of these synaptic defects in the amygdala are also amenable to pharmacological rescue. These results also underscore the need to modify the current hippocampus-centric framework to better explain FXS-related synaptic dysfunction in the amygdala.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21555214     DOI: 10.1016/j.conb.2011.04.005

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  12 in total

1.  Emotion recognition and visual-scan paths in Fragile X syndrome.

Authors:  Tracey A Shaw; Melanie A Porter
Journal:  J Autism Dev Disord       Date:  2013-05

2.  Psychophysiological responses to emotional stimuli in children and adolescents with autism and fragile X syndrome.

Authors:  Susannah Cohen; Katherine Masyn; Ann Mastergeorge; David Hessl
Journal:  J Clin Child Adolesc Psychol       Date:  2013-10-24

3.  Anandamide and 2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism based on FMR1 deletion in rats.

Authors:  Sara Schiavi; Antonia Manduca; Emilia Carbone; Valeria Buzzelli; Alessandro Rava; Alessandro Feo; Fabrizio Ascone; Maria Morena; Patrizia Campolongo; Matthew N Hill; Viviana Trezza
Journal:  Neuropsychopharmacology       Date:  2022-09-16       Impact factor: 8.294

4.  Emotion potentiated startle in fragile X syndrome.

Authors:  Elizabeth C Ballinger; Lisa Cordeiro; Alyssa D Chavez; Randi J Hagerman; David Hessl
Journal:  J Autism Dev Disord       Date:  2014-10

Review 5.  Molecular medicine of fragile X syndrome: based on known molecular mechanisms.

Authors:  Shi-Yu Luo; Ling-Qian Wu; Ran-Hui Duan
Journal:  World J Pediatr       Date:  2015-11-07       Impact factor: 2.764

Review 6.  The basolateral amygdala γ-aminobutyric acidergic system in health and disease.

Authors:  Eric M Prager; Hadley C Bergstrom; Gary H Wynn; Maria F M Braga
Journal:  J Neurosci Res       Date:  2015-11-19       Impact factor: 4.164

7.  Fear-specific amygdala function in children and adolescents on the fragile x spectrum: a dosage response of the FMR1 gene.

Authors:  So-Yeon Kim; Jessica Burris; Frederick Bassal; Kami Koldewyn; Sumantra Chattarji; Flora Tassone; David Hessl; Susan M Rivera
Journal:  Cereb Cortex       Date:  2012-11-11       Impact factor: 5.357

8.  Functional and structural deficits at accumbens synapses in a mouse model of Fragile X.

Authors:  Daniela Neuhofer; Christopher M Henstridge; Barna Dudok; Marja Sepers; Olivier Lassalle; István Katona; Olivier J Manzoni
Journal:  Front Cell Neurosci       Date:  2015-03-26       Impact factor: 5.505

Review 9.  Increasing our understanding of human cognition through the study of Fragile X Syndrome.

Authors:  Denise Cook; Erin Nuro; Keith K Murai
Journal:  Dev Neurobiol       Date:  2013-07-30       Impact factor: 3.964

10.  Experiential contributions to social dominance in a rat model of fragile-X syndrome.

Authors:  K Saxena; J Webster; A Hallas-Potts; R Mackenzie; P A Spooner; D Thomson; P Kind; S Chattarji; R G M Morris
Journal:  Proc Biol Sci       Date:  2018-06-13       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.